What question did this study set out to answer?

This trial aims to assess the effectiveness and safety of tislelizumab combined with standard treatments for advanced esophageal cancer.

April 12, 2026Journal of Clinical Oncology

Tislelizumab Combined With Induction Chemotherapy and Concurrent Chemoradiotherapy in Locally Advanced Esophageal Squamous Cell Carcinoma: A Multicenter, Randomized, Phase II Trial (EC-CRT-002)

View Full Paper

Ask AI

Bookmark

Authors

BCBaoqing Chen SLShiliang LiuSun Yat-sen University YZYujia ZhuSun Yat-sen University

Discussion

Member takes

Implication

Multicenter trial evaluates tislelizumab's effectiveness alongside chemotherapy and radiotherapy, suggesting beneficial outcomes for patients with advanced esophageal cancer.

Key Points

This trial aims to assess the effectiveness and safety of tislelizumab combined with standard treatments for advanced esophageal cancer.
Multicenter, randomized, open-label design
Participants aged 18-70 with unresectable stage II to IVB esophageal squamous cell carcinoma
Two treatment groups: Group A received two cycles of induction followed by concurrent CRT plus tislelizumab, and Group B received just induction and concurrent CRT
Primary endpoint was progression-free survival in the intention-to-treat population
Group B had significantly improved progression-free survival (PFS) compared to historical controls, with a 1-year PFS of 71.9%
Group A showed no significant PFS benefit with a 1-year PFS of 52.6%
Overall survival rates were better in Group B (HR 0.42) compared to Group A (HR 1.06)
Grade ≥3 adverse events were common, yet manageable, with lymphopenia being the most frequent

Cite This Study

Chen et al. (2026) studied this question.

synapsesocial.com/papers/69db383b4fe01fead37c670f https://doi.org/10.1200/jco-25-03044

View Full Paper

Ask AI

Bookmark

Implication

Multicenter trial evaluates tislelizumab's effectiveness alongside chemotherapy and radiotherapy, suggesting beneficial outcomes for patients with advanced esophageal cancer.

Tislelizumab Combined With Induction Chemotherapy and Concurrent Chemoradiotherapy in Locally Advanced Esophageal Squamous Cell Carcinoma: A Multicenter, Randomized, Phase II Trial (EC-CRT-002)

Discussion

Member takes

Implication

Key Points

Cite This Study

Tislelizumab Combined With Induction Chemotherapy and Concurrent Chemoradiotherapy in Locally Advanced Esophageal Squamous Cell Carcinoma: A Multicenter, Randomized, Phase II Trial (EC-CRT-002)

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider